ERAS earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -20.98. Updated 2026-07-23.
Erasca (ERAS) Research Hub
Erasca (ERAS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 15.88 USD (+1.15%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -20.98, market cap 6.06B. This hub links to the full technical, earnings and options research available for ERAS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.88 USD (+1.15%) |
| 52-week range | 13.42 USD – 21.6 USD |
| Trend regime | Range |
| 14-day RSI | 31.8 (Bearish) |
| Trailing P/E | -20.98 |
| Market cap | 6.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ERAS
Covered Call on ERAS: how it works, illustrative setup around the real 15.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ERAS: how it works, illustrative setup around the real 15.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ERAS: how it works, illustrative setup around the real 15.88 USD price, max profit/loss, breakeven and when to use it. Educational.
ERAS technical analysis: range, last 15.88 USD, RSI 31.8, 52w range 13.42 USD–21.6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ERAS in?
Erasca (ERAS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ERAS in an uptrend or downtrend?
As of 2026-09-11, ERAS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ERAS's trailing P/E ratio?
ERAS's trailing P/E is -20.98, with a market cap of 6.06B. See the earnings research page for full valuation detail.
When does ERAS next report earnings?
ERAS is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.12 USD.